Showing 8421-8430 of 8647 results for "".
- RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapyhttps://modernod.com/news/radiancetx-raises-1-million-first-tranche-to-develop-novel-glaucoma-therapy/2479970/RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three cli
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- Unsafe Ocular Stem Cell Treatments Prevalenthttps://modernod.com/news/unsafe-ocular-stem-cell-treatments-prevalent/2479976/Experimental stem cell therapies for eye conditions are being offered at dozens of unregulated clinics in the United States, and some of these procedures are harmful, researchers report. Clinicians should warn their patients against
- Visual Function Problems May Be More Common in Children With Dyslexiahttps://modernod.com/news/visual-function-problems-may-be-more-common-in-children-with-dyslexia/2479977/Children with developmental dyslexia (DD) may be more likely to have visual deficits than their typically developing peers, a study suggests, according to a report in Reuters. Nearly 80% of the DD group had a deficit in at least one
- Eton Pharma Reports Positive Topline Results from Phase 3 Trial of EM-100https://modernod.com/news/eton-pharma-reports-positive-topline-results-from-phase-3-trial-of-em-100/2479990/Eton Pharmaceuticals announced positive topline results for its phase 3 study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation
- Omeros Corporation Initiates Sales of Omidria in Europehttps://modernod.com/news/omeros-corporation-initiates-sales-of-omidria-in-europe/2479997/Omeros announced initial sales of »Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. Omidria, approved and commercially available in the United
- Report Highlights New Health Concern for Rohingya Refugees: Eye Health & Needed Treatment for Preventable Blindnesshttps://modernod.com/news/report-highlights-new-health-concern-for-rohingya-refugees-eye-health-needed-treatment-for-preventable-blindness/2480003/The Seva Foundation, an international eye health and blindness-prevention organization, recently released a new report to assess the eye care needs of the one million Rohingya people living in refugee camps in Bangladesh.
- BlephEx Names Fred Ellis CEOhttps://modernod.com/news/blephex-names-fred-ellis-ceo/2480014/BlephEx has announced that Fred Ellis is the company’s new CEO. Mr. Ellis comes to BlephEx with 29+ years of experience with Alcon-Novartis. While there, he held numerous positions of increased responsibility overseeing a wide range of commercial assignments. He is recognized for having exception
- Sheraz Daya, MD, Introduces the Daya ICL Forcepshttps://modernod.com/news/sheraz-daya-md-introduces-the-daya-icl-forceps/2480015/In partnership with MST, Sheraz Daya, MD, has co-created an ICL loading system that ensures true confidence in loading and positioning. The design of the forceps allow the user to pull the ICL into the injection cartr
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi